Combination of 90Y- and 177Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to 90Y- or 177Lu-labeled analogs only.

被引：0
|
作者：
De Jong, M [1 ]
Bernard, HF [1 ]
Breeman, WA [1 ]
Van Gameren, A [1 ]
Krenning, EP [1 ]
机构：
[1] Erasmus MC, Rotterdam, Netherlands
来源：
JOURNAL OF NUCLEAR MEDICINE | 2002年 / 43卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
446
引用
收藏
页码：123P / 124P
页数：2
相关论文
共 50 条
  • [1] Response to radionuclide therapy using 90Y- and 177Lu-labeled somatostatin analogs is dependent on tumor size.
    De Jong, M
    Breeman, WA
    Bernard, HF
    Van Gameren, A
    Van Harskamp, E
    Bakker, WH
    Bugaj, JE
    Erion, JL
    Krenning, EP
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 125P - 126P
  • [2] Preparation and characterization of 90Y- and 177Lu-labeled cetuximab for therapeutic applications in vitro and in vivo
    Zenker, Martin
    Bergmann, Ralf
    Walther, Martin
    Heldt, Jan-Martin
    Pietzsch, Jens
    Pietzsch, Hans-Juergen
    Steinbach, Joerg
    NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (06) : 723 - 723
  • [3] Combination radionuclide therapy using 177Lu- and 90Y-Labeled somatostatin analogs
    de Jong, M
    Breeman, WAP
    Valkema, R
    Bernard, BF
    Krenning, EP
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 : 13S - 17S
  • [4] Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues
    Miao, Yubin
    Fisher, Darrell R.
    Quinn, Thomas P.
    NUCLEAR MEDICINE AND BIOLOGY, 2006, 33 (06) : 723 - 733
  • [5] Tumor-targeting properties of 90Y- and 177Lu-labeled α-melanocyte stimulating hormone peptide analogues in a murine melanoma model
    Miao, YB
    Hoffman, TJ
    Quinn, TP
    NUCLEAR MEDICINE AND BIOLOGY, 2005, 32 (05) : 485 - 493
  • [6] 99mTc-, 90Y-, and 177Lu-Labeled Iron Oxide Nanoflowers Designed for Potential Use in Dual Magnetic Hyperthermia/Radionuclide Cancer Therapy and Diagnosis
    Ognjanovic, Milos
    Radovic, Magdalena
    Mirkovic, Marija
    Prijovic, Zeljko
    Morales, Maria del Puerto
    Ceh, Miran
    Vranjes-Duric, Sanja
    Antic, Bratislav
    ACS APPLIED MATERIALS & INTERFACES, 2019, 11 (44) : 41109 - 41117
  • [7] Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies:: Effect of multiple treatments on myelotoxicity
    Vallabhajosula, S
    Goldsmith, SJ
    Kostakoglu, L
    Milowsky, MI
    Nanus, DM
    Bander, NH
    CLINICAL CANCER RESEARCH, 2005, 11 (19) : 7195S - 7200S
  • [8] Dosimetry evaluation in 177Lu-labeled somatostatin analogue therapy
    Cichonski, A.
    Wrobel, Kempinska M.
    Cwikla, J. B.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 179 - 179
  • [9] Dosimetry evaluation in 177Lu-labeled somatostatin receptor analogue therapy
    Cichonski, A.
    Kempinska-Wrobel, M.
    Kolasinska-Cwikla, A.
    Zrajkowska, A.
    Szarowicz, A.
    Cwikla, J. B.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 181 - 181
  • [10] Response to radionuclide therapy using 90Y- and 111In-labeled somatostatin analogs is dependent on tumor size.
    De Jong, M
    Breeman, WA
    Bernard, HF
    Van Gameren, A
    Schaar, M
    Bakker, WH
    Krenning, EP
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 147P - 147P
12345